Nick Scott

List of Publications by Year
in descending order

74 papers	2,790 citations	236925 25 h-index	206112 48 g-index
81 all docs	81 docs citations	81 times ranked	3266 citing authors

#	Article	IF	Citations
1	Covasim: An agent-based model of COVID-19 dynamics and interventions. PLoS Computational Biology, 2021, 17, e1009149.	3.2	330
2	Impacts of COVID-19 on childhood malnutrition and nutrition-related mortality. Lancet, The, 2020, 396, 519-521.	13.7	296
3	The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	13.7	257
4	Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut, 2017, 66, 1507-1515.	12.1	119
5	The COVID-19 crisis will exacerbate maternal and child undernutrition and child mortality in low- and middle-income countries. Nature Food, 2021, 2, 476-484.	14.0	117
6	Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. International Journal of Drug Policy, 2017, 47, 107-116.	3.3	114
7	Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduction Journal, 2013, 10, 11.	3.2	82
8	Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. Journal of Hepatology, 2019, 70, 839-846.	3.7	80
9	High-frequency drug purity and price series as tools for explaining drug trends and harms in Victoria, Australia. Addiction, 2015, 110, 120-128.	3.3	61
10	Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. Clinical Infectious Diseases, 2020, 70, 1900-1906.	5.8	61
11	Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30. The Lancet Global Health, 2019, 7, e1180-e1188.	6.3	58
12	Modelling the impact of relaxing COVID-19 control measures during a period of low viral transmission. Medical Journal of Australia, 2021, 214, 79-83.	1.7	58
13	Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020. Journal of Hepatology, 2018, 68, 932-939.	3.7	53
14	Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study. Harm Reduction Journal, 2020, 17, 14.	3.2	51
15	A global investment framework for the elimination of hepatitis B. Journal of Hepatology, 2021, 74, 535-549.	3.7	51
16	Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 872-882.	2.8	47
17	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver International, 2019, 39, 1818-1836.	3.9	44
18	Australia needs to increase testing to achieve hepatitis C elimination. Medical Journal of Australia, 2020, 212, 365-370.	1.7	43

#	Article	IF	Citations
19	An urgent need to scale-up injecting drug harm reduction services in Tanzania: Prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011. International Journal of Drug Policy, 2013, 24, 78-81.	3.3	38
20	Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. The Lancet Global Health, 2018, 6, e659-e667.	6.3	36
21	Treatment access is only the first step to hepatitis C elimination: experience of universal antiviral treatment access in Australia. Alimentary Pharmacology and Therapeutics, 2019, 49, 1223-1229.	3.7	34
22	Optimally capturing latency dynamics in models of tuberculosis transmission. Epidemics, 2017, 21, 39-47.	3.0	31
23	Ending malnutrition in all its forms requires scaling up proven nutrition interventions and much more: a 129-country analysis. BMC Medicine, 2020, 18, 356.	5.5	29
24	Longitudinal changes in psychological distress in a cohort of people who inject drugs in Melbourne, Australia. Drug and Alcohol Dependence, 2016, 168, 140-146.	3.2	28
25	Achieving 90-90-90 Human Immunodeficiency Virus (HIV) Targets Will Not Be Enough to Achieve the HIV Incidence Reduction Target in Australia. Clinical Infectious Diseases, 2018, 66, 1019-1023.	5.8	28
26	Global hepatitis C elimination: an investment framework. The Lancet Gastroenterology and Hepatology, 2020, 5, 927-939.	8.1	28
27	Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in highprevalence settings. Journal of Viral Hepatitis, 2018, 25, 1472-1480.	2.0	27
28	Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe directacting antiviral therapy for hepatitis C. Journal of Viral Hepatitis, 2018, 25, 1089-1098.	2.0	26
29	A model of the economic benefits of global hepatitis C elimination: an investment case. The Lancet Gastroenterology and Hepatology, 2020, 5, 940-947.	8.1	26
30	Optima Nutrition: an allocative efficiency tool to reduce childhood stunting by better targeting of nutrition-related interventions. BMC Public Health, 2018, 18, 384.	2.9	24
31	Eliminating hepatitis C virus as a public health threat among <scp>HIV</scp>positive men who have sex with men: a multimodelling approach to understand differences in sexual risk behaviour. Journal of the International AIDS Society, 2018, 21, e25059.	3.0	21
32	The effects of extended public transport operating hours and venue lockout policies on drinking-related harms in Melbourne, Australia: Results from SimDrink, an agent-based simulation model. International Journal of Drug Policy, 2016, 32, 44-49.	3.3	20
33	Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries. BMC Medicine, 2019, 17, 208.	5.5	20
34	Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study. The Lancet Global Health, 2020, 8, e931-e941.	6.3	19
35	Role of masks, testing and contact tracing in preventing COVID-19 resurgences: a case study from New South Wales, Australia. BMJ Open, 2021, 11, e045941.	1.9	18
36	The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Medicine, 2019, 17, 175.	5.5	17

#	Article	IF	Citations
37	A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. International Journal of Drug Policy, 2020, 76, 102633.	3.3	17
38	Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. Virulence, 2016, 7, 201-208.	4.4	16
39	Heavy drinking occasions in <scp>A</scp>ustralia: Do context and beverage choice differ from low‑risk drinking occasions?. Drug and Alcohol Review, 2014, 33, 354-357.	2.1	15
40	Cohort Profile: The Melbourne Injecting Drug User Cohort Study (SuperMIX). International Journal of Epidemiology, 2022, 51, e123-e130.	1.9	14
41	SimDrink: An Agent-Based NetLogo Model of Young, Heavy Drinkers for Conducting Alcohol Policy Experiments. Jasss, 2016, 19, .	1.8	13
42	Longitudinal analysis of change in individual-level needle and syringe coverage amongst a cohort of people who inject drugs in Melbourne, Australia. Drug and Alcohol Dependence, 2017, 176, 7-13.	3.2	12
43	The Prison and Transition Health (PATH) cohort study: Prevalence of health, social, and crime characteristics after release from prison for men reporting a history of injecting drug use in Victoria, Australia. Drug and Alcohol Dependence, 2021, 227, 108970.	3.2	12
44	Determining the effective dose of street-level heroin: A new way to consider fluctuations in heroin purity, mass and potential contribution to overdose. Forensic Science International, 2018, 290, 219-226.	2.2	11
45	Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model. International Journal of Drug Policy, 2021, 88, 102634.	3.3	11
46	Prevalence and correlates of simultaneous, multiple substance injection (co‑injection) among people who inject drugs in Melbourne, Australia. Addiction, 2021, 116, 876-888.	3.3	10
47	Understanding alcohol and other drug use during the event. Drug and Alcohol Review, 2014, 33, 335-337.	2.1	9
48	Enhancing the hepatitis B care cascade in Australia: A cost‑effectiveness model. Journal of Viral Hepatitis, 2020, 27, 526-536.	2.0	9
49	Preventing a cluster from becoming a new wave in settings with zero community COVID-19 cases. BMC Infectious Diseases, 2022, 22, 232.	2.9	9
50	Achieving hepatitis C elimination in Europe â€" To treatment scale-up and beyond. Journal of Hepatology, 2018, 68, 383-385.	3.7	8
51	A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison. International Journal of Drug Policy, 2021, 94, 103203.	3.3	8
52	Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. PLoS Medicine, 2021, 18, e1003818.	8.4	8
53	Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access. Journal of Virus Eradication, 2018, 4, 108-114.	0.5	8
54	Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020. International Journal of Drug Policy, 2022, 103, 103655.	3.3	8

#	Article	IF	Citations
55	Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection. Scientific Reports, 2020, 10, 1459.	3.3	7
56	How does the use of multiple needles/syringes per injecting episode impact on the measurement of individual level needle and syringe program coverage?. International Journal of Drug Policy, 2017, 46, 99-106.	3.3	6
57	Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure. International Journal of Drug Policy, 2020, 75, 102596.	3.3	6
58	Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. The Lancet Regional Health - Western Pacific, 2021, 10, 100129.	2.9	6
59	Modelling the impact of migrants on the success of the HIV care and treatment program in Botswana. PLoS ONE, 2020, 15, e0226422.	2.5	5
60	Patterns of drug preference and use among people who inject drugs in Melbourne, Australia. Addiction Research and Theory, 2015, 23, 459-468.	1.9	4
61	Analysis of time of drug use according to needle and syringe program operating hours in Melbourne, Australia: Effects on individual-level needle and syringe coverage. Drug and Alcohol Dependence, 2018, 191, 259-265.	3.2	4
62	Estimating the syphilis epidemic among gay, bisexual and other men who have sex with men in Australia following changes in HIV care and prevention. Sexual Health, 2019, 16, 254-262.	0.9	4
63	Measuring hepatitis C virus elimination as a public health threat: Beyond global targets. Journal of Viral Hepatitis, 2020, 27, 770-773.	2.0	4
64	Blood donation amongst people who inject drugs in Australia: research supporting policy change. Vox Sanguinis, 2020, 115, 162-170.	1.5	4
65	Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. The Lancet Regional Health - Western Pacific, 2022, 18, 100316.	2.9	4
66	Using simulation modelling to examine the impact of venue lockout and last-drink policies on drinking-related harms and costs to licensees. Australian and New Zealand Journal of Public Health, 2017, 41, 243-247.	1.8	3
67	The pitfalls of prevalence estimation: the case of regular and dependent methamphetamine use in Australia. Addiction Research and Theory, 2018, 26, 439-446.	1.9	3
68	Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2270-2274.	2.8	3
69	A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign. Journal of Viral Hepatitis, 2021, 28, 1624-1634.	2.0	2
70	Eliminating hepatitis C virus from HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. Journal of Hepatology, 2017, 66, S413.	3.7	1
71	Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019. Epidemiology and Infection, 2022, 150, e7.	2.1	1
72	How is methamphetamine typically purchased and used in Melbourne, Australia? Reports from a cohort of people who inject drugs. Addiction Research and Theory, 2016, 24, 416-425.	1.9	0

#	Article	IF	Citations
73	Authors' response to Letter to the Editor: 'Colombian experience in the management of hepatitis C'. Liver International, 2020, 40, 3142-3143.	3.9	0
74	Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol. BMJ Open, 2022, 12, e056120.	1.9	0